Cargando…
Author Correction: Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366119/ https://www.ncbi.nlm.nih.gov/pubmed/37488181 http://dx.doi.org/10.1038/s41598-023-39009-5 |
| _version_ | 1785077101373685760 |
|---|---|
| author | Matsumoto, Toshihiko Ikoma, Tatsuki Yamamura, Shogo Miura, Kou Tsuduki, Takao Watanabe, Takanori Nagai, Hiroki Takatani, Masahiro Yasui, Hisateru |
| author_facet | Matsumoto, Toshihiko Ikoma, Tatsuki Yamamura, Shogo Miura, Kou Tsuduki, Takao Watanabe, Takanori Nagai, Hiroki Takatani, Masahiro Yasui, Hisateru |
| author_sort | Matsumoto, Toshihiko |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10366119 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103661192023-07-26 Author Correction: Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab Matsumoto, Toshihiko Ikoma, Tatsuki Yamamura, Shogo Miura, Kou Tsuduki, Takao Watanabe, Takanori Nagai, Hiroki Takatani, Masahiro Yasui, Hisateru Sci Rep Author Correction Nature Publishing Group UK 2023-07-24 /pmc/articles/PMC10366119/ /pubmed/37488181 http://dx.doi.org/10.1038/s41598-023-39009-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Author Correction Matsumoto, Toshihiko Ikoma, Tatsuki Yamamura, Shogo Miura, Kou Tsuduki, Takao Watanabe, Takanori Nagai, Hiroki Takatani, Masahiro Yasui, Hisateru Author Correction: Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab |
| title | Author Correction: Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab |
| title_full | Author Correction: Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab |
| title_fullStr | Author Correction: Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab |
| title_full_unstemmed | Author Correction: Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab |
| title_short | Author Correction: Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab |
| title_sort | author correction: regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab |
| topic | Author Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366119/ https://www.ncbi.nlm.nih.gov/pubmed/37488181 http://dx.doi.org/10.1038/s41598-023-39009-5 |
| work_keys_str_mv | AT matsumototoshihiko authorcorrectionregorafenibissuitableforadvancedcolorectalcancerpatientswhohavepreviouslyreceivedtrifluridinetipiracilplusbevacizumab AT ikomatatsuki authorcorrectionregorafenibissuitableforadvancedcolorectalcancerpatientswhohavepreviouslyreceivedtrifluridinetipiracilplusbevacizumab AT yamamurashogo authorcorrectionregorafenibissuitableforadvancedcolorectalcancerpatientswhohavepreviouslyreceivedtrifluridinetipiracilplusbevacizumab AT miurakou authorcorrectionregorafenibissuitableforadvancedcolorectalcancerpatientswhohavepreviouslyreceivedtrifluridinetipiracilplusbevacizumab AT tsudukitakao authorcorrectionregorafenibissuitableforadvancedcolorectalcancerpatientswhohavepreviouslyreceivedtrifluridinetipiracilplusbevacizumab AT watanabetakanori authorcorrectionregorafenibissuitableforadvancedcolorectalcancerpatientswhohavepreviouslyreceivedtrifluridinetipiracilplusbevacizumab AT nagaihiroki authorcorrectionregorafenibissuitableforadvancedcolorectalcancerpatientswhohavepreviouslyreceivedtrifluridinetipiracilplusbevacizumab AT takatanimasahiro authorcorrectionregorafenibissuitableforadvancedcolorectalcancerpatientswhohavepreviouslyreceivedtrifluridinetipiracilplusbevacizumab AT yasuihisateru authorcorrectionregorafenibissuitableforadvancedcolorectalcancerpatientswhohavepreviouslyreceivedtrifluridinetipiracilplusbevacizumab |